Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Correlation Between Carbapenemase-Producing Enterobacterales Load, Environmental Contamination, and Transmission in Critical Care Units (CPE-Load ICU S)

29 juin 2026 mis à jour par: MARIA INES STANELONI, Hospital Italiano de Buenos Aires

Carbapenemase-producing Enterobacterales (CPE) are multidrug-resistant bacteria that can colonize the gastrointestinal tract of hospitalized patients and spread within intensive care units (ICUs). Some colonized individuals may carry a particularly high bacterial burden and contribute disproportionately to environmental contamination and transmission to other patients. Identifying these high-risk individuals could improve infection prevention and control strategies.

This prospective observational study will be conducted in the Adult Intensive Care Unit of Hospital Italiano de Buenos Aires. Patients identified as colonized with CPE through routine surveillance will undergo quantitative culture and real-time polymerase chain reaction (PCR) testing of rectal swabs to measure bacterial load. Environmental samples will also be collected from high-touch surfaces surrounding colonized patients. In selected cases, molecular typing methods will be used to evaluate genetic relatedness between patient and environmental isolates and to investigate possible transmission events.

The primary objective is to determine the correlation between bacterial load measured by culture and the PCR cycle threshold (Ct) value. Secondary objectives include evaluating the association between bacterial load and environmental contamination, and assessing whether patients with higher bacterial loads are more likely to contribute to transmission within the ICU. Results may help identify patients with increased dissemination potential and support targeted infection prevention interventions.

Aperçu de l'étude

Description détaillée

Carbapenemase-producing Enterobacterales (CPE) represent a major global public health threat because of their extensive antimicrobial resistance and their ability to spread within healthcare facilities. Gastrointestinal colonization is recognized as the main reservoir for transmission. Previous studies have suggested that a subset of colonized patients, often referred to as "super-spreaders," carry a substantially higher bacterial burden and may account for a disproportionate share of environmental contamination and transmission events.

Although bacterial load can be quantified using culture-based and molecular methods, there is currently no validated cycle threshold (Ct) value from routinely used real-time PCR assays that reliably identifies patients with high dissemination potential. Establishing a correlation between Ct values and bacterial burden could provide a practical and accessible tool for infection prevention programs.

This prospective observational cohort study will be conducted in the Adult Intensive Care Unit of Hospital Italiano de Buenos Aires. All patients identified through the institutional surveillance program as colonized with CPE will be eligible for inclusion. For each CPE-positive patient, rectal swabs obtained as part of routine surveillance will undergo quantitative culture on selective chromogenic media and molecular testing using real-time PCR targeting carbapenemase genes. Bacterial load will be estimated using colony-forming unit counts and PCR Ct values.

Environmental contamination will be assessed through systematic sampling of high-touch surfaces in the patient's surroundings, including bed linen, bedside furniture, and medical equipment. Environmental isolates will undergo microbiological and molecular characterization. In selected situations, whole genome sequencing or pulsed-field gel electrophoresis will be performed to evaluate genetic relatedness among isolates recovered from patients, environmental samples, and secondary cases.

The primary outcome is the correlation between quantitative bacterial load and PCR Ct values. Secondary outcomes include the extent of environmental contamination associated with different bacterial loads and the occurrence of transmission events involving genetically related strains. Multivariable analyses will evaluate the influence of relevant clinical and epidemiological factors, including length of stay, fecal incontinence, prior antimicrobial exposure, immunosuppression, and other potential confounders.

The study involves minimal risk because all patient samples are obtained within the framework of routine infection control surveillance. Findings from this study may improve the identification of patients with increased transmission potential and support more targeted and efficient infection prevention strategies in critical care settings.

Type d'étude

Observationnel

Inscription (Estimé)

60

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Buenos Aires F.D.
      • Buenos Aires, Buenos Aires F.D., Argentine, 1199
        • Hospital Italiano de Buenos Aires
        • Contact:
        • Contact:
        • Chercheur principal:
          • Maria Ines Staneloni, MD
        • Sous-enquêteur:
          • Emilio Felipe Huaier Arriazu, MD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Adult patients hospitalized in the Adult Intensive Care Unit of Hospital Italiano de Buenos Aires during the study period, with a positive surveillance rectal swab for carbapenemase-producing Enterobacterales detected through the institutional infection control surveillance program.

La description

Inclusion Criteria

  • Age 18 years or older.
  • Hospitalized in the Adult Intensive Care Unit of Hospital Italiano de Buenos Aires during the study period.
  • Positive surveillance rectal swab for carbapenemase-producing Enterobacterales.

Exclusion Criteria

-Patients colonized or infected with carbapenemase-producing Enterobacterales who remained in the same room for less than 48 hours.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

Cohortes et interventions

Groupe / Cohorte
CPE-Colonized ICU Patients
Patients admitted to the Adult Intensive Care Unit of Hospital Italiano de Buenos Aires with a positive surveillance rectal swab for carbapenemase-producing Enterobacterales (CPE). Participants will undergo quantitative culture and real-time PCR testing of rectal swabs as part of routine surveillance. Environmental samples will be collected from high-touch surfaces surrounding colonized patients to evaluate environmental contamination and transmission dynamics.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Correlation Between PCR Cycle Threshold (Ct) Value and Quantitative Bacterial Load (CFU/swab) in Rectal Surveillance Swabs
Délai: At baseline (time of positive rectal surveillance swab)
Spearman correlation coefficient between the cycle threshold (Ct) value obtained by real-time PCR (BD MAX™ system) targeting carbapenemase genes and the quantitative bacterial load measured by culture on CHROMagar™ KPC selective medium, expressed as colony-forming units per swab (CFU/swab), from rectal surveillance swabs positive for carbapenemase-producing Enterobacterales.
At baseline (time of positive rectal surveillance swab)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Correlation Between Quantitative Bacterial Load (CFU/swab) in Rectal Swabs and Number of CPE-Positive High-Touch Environmental Surfaces
Délai: Within 24 hours of rectal swab collection
Spearman correlation coefficient between the quantitative bacterial load of carbapenemase-producing Enterobacterales in rectal surveillance swabs, measured by culture on CHROMagar™ KPC selective medium and expressed as colony-forming units per swab (CFU/swab), and the number of CPE-positive high-touch surfaces out of 5 sampled (bed linen, bedside table, and infusion pump), assessed by quantitative culture on CHROMagar™ KPC contact plates.
Within 24 hours of rectal swab collection
Correlation Between PCR Cycle Threshold (Ct) Value in Rectal Swabs and Number of CPE-Positive High-Touch Environmental Surfaces
Délai: Within 24 hours of rectal swab collection
Spearman correlation coefficient between the cycle threshold (Ct) value obtained by real-time PCR (BD MAX™ system) targeting carbapenemase genes from rectal surveillance swabs positive for carbapenemase-producing Enterobacterales, and the number of CPE-positive high-touch surfaces out of 5 sampled (bed linen, bedside table, and infusion pump), assessed by quantitative culture on CHROMagar™ KPC contact plates.
Within 24 hours of rectal swab collection
Correlation Between Quantitative Bacterial Load (CFU/swab) in Rectal Swabs and Total Colony-Forming Units Recovered from Environmental Surfaces
Délai: Within 24 hours of rectal swab collection
Spearman correlation coefficient between the quantitative bacterial load of carbapenemase-producing Enterobacterales in rectal surveillance swabs, measured by culture on CHROMagar™ KPC selective medium and expressed as colony-forming units per swab (CFU/swab), and the total colony-forming units (CFU) recovered across five high-touch surfaces (bed linen, bedside table, and infusion pump) surrounding colonized patients, assessed by quantitative culture on CHROMagar™ KPC contact plates.
Within 24 hours of rectal swab collection
Correlation Between PCR Cycle Threshold (Ct) Value in Rectal Swabs and Total Colony-Forming Units Recovered from Environmental Surfaces
Délai: Within 24 hours of rectal swab collection
Spearman correlation coefficient between the cycle threshold (Ct) value obtained by real-time PCR (BD MAX™ system) targeting carbapenemase genes from rectal surveillance swabs positive for carbapenemase-producing Enterobacterales, and the total colony-forming units (CFU) recovered across five high-touch surfaces (bed linen, bedside table, and infusion pump) surrounding colonized patients, assessed by quantitative culture on CHROMagar™ KPC contact plates.
Within 24 hours of rectal swab collection
Number of Index Patients with Transmission of at Least One Genetically Related CPE Strain to a Co-Hospitalized Patient
Délai: Up to 6 months
Number of index patients associated with at least one secondary case carrying a genetically related carbapenemase-producing Enterobacterales strain, confirmed by whole genome sequencing (WGS) and/or pulsed-field gel electrophoresis (PFGE), among patients hospitalized in the same intensive care unit during the study period.
Up to 6 months
Number of Patients Meeting Predefined Criteria for Super-Spreader Classification
Délai: At baseline (time of CPE detection and environmental sampling)
Number of CPE-colonized patients classified as potential super-spreaders, defined post-hoc as having a cycle threshold (Ct) value below the 25th percentile of the study population and at least 2 positive environmental surfaces with more than 50 colony-forming units (CFU) each, assessed by quantitative culture on CHROMagar™ KPC contact plates.
At baseline (time of CPE detection and environmental sampling)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Maria Ines Staneloni, MD, Hospital Italiano de Buenos Aires

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 août 2026

Achèvement primaire (Estimé)

31 décembre 2026

Achèvement de l'étude (Estimé)

15 janvier 2027

Dates d'inscription aux études

Première soumission

9 juin 2026

Première soumission répondant aux critères de contrôle qualité

29 juin 2026

Première publication (Réel)

6 juillet 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

6 juillet 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

29 juin 2026

Dernière vérification

1 juin 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Individual participant data underlying the results reported in publications will be available after de-identification. Data may be shared with qualified researchers upon reasonable request to the principal investigator and after approval by the Hospital Italiano de Buenos Aires Ethics Committee, in accordance with institutional policies and applicable regulations regarding data protection and patient confidentiality.

What IPD Will Be Shared? De-identified demographic data Clinical characteristics Rectal swab quantitative culture results PCR cycle threshold (Ct) values Environmental sampling results Molecular characterization and genomic data used in analyses Derived study variables

Délai de partage IPD

Beginning 6 months after publication and ending 5 years after publication.

Critères d'accès au partage IPD

Researchers who provide a methodologically sound proposal may access de-identified participant data for scientific purposes. Requests will be reviewed by the principal investigator and the institutional ethics committee. Data sharing agreements may be required before data release.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • ANALYTIC_CODE
  • RSE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner